Article Information
History
- October 29, 2020.
Article Versions
- Version 1 (August 21, 2020 - 20:00).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Aitana Juan-Giner, MSc1,*,
- Derick Kimathi, MBChB2,3,*,
- Kyra H. Grantz, BA4,5,6,
- Mainga M. Hamaluba, MD2,
- Patrick Kazooba, MBChB7,
- Patricia Njuguna, MMed2,
- Gamou Fall, PhD8,
- Moussa Dia, MSc8,
- Ndeye S. Bob, PhD8,
- Thomas P. Monath, MD9,
- Alan D. Barrett, PhD10,
- Joachim Hombach, PhD11,
- Edgar M. Mulogo, PhD12,
- Immaculate Ampeire, MBChB13,
- Henry K. Karanja, MSc2,
- Dan Nyehangane, MSc7,
- Juliet Mwanga-Amumpaire, MMed7,
- Derek A.T. Cummings, PhD4,5,
- Prof Philip Bejon2,3,
- George M. Warimwe, PhD2,3,# and
- Rebecca F. Grais, PhD1,#,†
- 1Epicentre, Paris, France
- 2Kenya Medical Research Institute – Wellcome Trust Research Programme, Kilifi, Kenya
- 3Centre for Tropical Medicine & Global Health, University of Oxford, UK
- 4Department of Biology, University of Florida
- 5Emerging Pathogens Institute, University of Florida
- 6Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health
- 7Epicentre Mbarara Research Centre, Uganda
- 8Institut Pasteur Dakar, Senegal
- 9Crozet BioPharma LLC, Devens MA, USA
- 10Sealy Institute for Vaccines Sciences and Department of Pathology, University of Texas Medical Branch, USA
- 11Immunization, Vaccines & Biologicals, World Health Organization, Geneva, Switzerland
- 12Department of Community Health, Mbarara University of Science & Technology, Uganda
- 13Expanded Program on Immunization, Ministry of Health, Uganda
- ↵†Corresponding author: Rebecca F Grais; Address: 34 Avenue Jean Jaurès, 75019 Paris, France; Tel: +33 (0) 1 40 21 54 75; Email: rebecca.grais{at}epicentre.msf.org
Posted October 29, 2020.
Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomized, double-blind, non-inferiority trial
